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Abstract
Background: In this study, we sought to evaluate the prevalence of metabolic syndrome (MS) in
a cohort of pregnant women with a wide range of glucose tolerance, prepregnancy risk factors for
MS during pregnancy, and the effects of MS in the outcomes in the mother and in the newborn.
Methods: One hundred and thirty six women with positive screening for gestational diabetes
mellitus (GDM) were classified by two diagnostic methods: glycemic profile and 100 g OGTT as
normoglycemic, mild gestational hyperglycemic, GDM, and overt GDM. Markers of MS were
measured between 2428th during the screening.
Results:  The prevalence of MS was: 0%; 20.0%; 23.5% and 36.4% in normoglycemic, mild
hyperglycemic, GDM, and overt GDM groups, respectively. Previous history of GDM with or
without insulin use, BMI ≥ 25, hypertension, family history of diabetes in first degree relatives, non-
Caucasian ethnicity, history of prematurity and polihydramnios were statistically significant
prepregnancy predictors for MS in the index pregnancy, that by its turn increased the adverse
outcomes in the mother and in the newborn.
Conclusion: The prevalence of MS increases with the worsening of glucose tolerance; impaired
glycemic profile identifies pregnancies with important metabolic abnormalities even in the presence
of a normal OGTT, in patients that are not classified as having GDM.
Background
Short and long-term important consequences for the
fetus, the newborn and the mother can occur when gesta-
tional diabetes mellitus (GDM) is present [1,2]. Pregnant
women that show mild hyperglycemia, but do not meet
the criteria for GDM diagnosis can still present glucose-
mediated macrosomia, the same perinatal mortality rate
and adverse pregnancy and perinatal outcomes as those
with GDM [3-11].
Typically, a condition of insulin resistance develops in the
second and third trimester of pregnancy. The impairment
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of insulin sensitivity makes pregnancy a diabetogenic con-
dition. Nonetheless, only 3 to 5% of women develop
GDM [12,13]. As it happens in type 2 diabetes mellitus
(DM2) and in metabolic syndrome (MS), when dysglyc-
emia is present, GDM is associated to both insulin resist-
ance and impaired insulin secretion [14-16]. DM2, MS
and GDM also share the same risk factors and have a cor-
responding prevalence within a given population and the
same genetic susceptibility [17]. Many of the known met-
abolic components of the MS are predictive of GDM,
which could be considered as one phase of the MS. MS is
referred to the association of hyperinsulinemia, insulin
resistance, visceral obesity, dyslipidemia, hypertension,
and DM2 or impaired glucose tolerance [18]. These fea-
tures increase the risk of atherosclerosis and coronary
heart disease [19,20]. It is not known whether mild
degrees of hyperglycemia are also associated to the com-
ponents of MS and adverse pregnancy outcomes.
Thus, the aims of this study were to evaluate the preva-
lence of MS through the presence of its physical and clin-
ical components in a cohort of pregnant women with a
wide range of glucose tolerance and to analyze prepreg-
nancy risk factors for the development of MS during preg-
nancy and its adverse impacts on pregnancy outcomes.
Research design, patients and methods
This study was approved by the Institutional Review
Board of the School of Medicine of Botucatu  São Paulo
State University  UNESP, Brazil; where it was conducted
from April 2004 through November 2005. One hundred
and thirty six women with singleton pregnancies were
assigned to participate if they presented a fasting glycemia
level ≥ 90 mg/dl and/or risk factors for developing GDM.
Between the 24th through 28th weeks of gestation, a 100 g
OGTT and a glycemic profile were performed. The cutoff
values for the OGTT were those proposed by Carpenter &
Coustan (fasting ≥ 95 mg/dl; 1 hour ≥ 180 mg/dl; 2 hours
≥ 155 mg/dl; 3 hours ≥ 140 mg/dl) [21] and for the glyc-
emic profile those proposed by Gillmer et al. (fasting ≥ 90
mg/dl and 1 hour post prandial ≥ 130 mg/dl) [22]. The
glycemic profile was performed a week after the OGTT.
Patients were taught on how to measure their glycemic
levels using a glucometer in the fasting state at 8:00
o'clock AM, then post-prandial at 10:00 o'clock AM, mid-
day, 2, 4 and 6 o'clock PM. If the results were borderline
(10 mg/dl higher or lower than the cutoff values) they
were repeated. After these procedures they were classified
in four groups:
IA Group  Normal OGTT and glycemic profile (normogly-
cemic or control group)
IB Group  Normal OGTT and abnormal glycemia profile
(mild hyperglycemic group)
IIA Group  Abnormal OGTT and normal glycemic profile
(gestational diabetes group)
IIB Group  Abnormal OGTT and glycemic profile (overt
gestational diabetes group)
Maternal characteristics such as age, parity, ethnicity, edu-
cational level, family income (Brazilian minimum wage),
weight and length at birth, weight and prepregnancy body
mass index (BMI), family's history of diabetes, hyperten-
sion, obesity, and dyslipidemia were recorded. At screen-
ing, weight, height, legs length, blood pressure, waist
circumference, and hip circumference were measured.
Obesity was defined as a prepregnancy body mass index
(BMI) ≥ 30 kg/m2. Hypertension was considered when a
systolic blood pressure >140 mmHg or a diastolic blood
pressure > 90 mmHg, on at least two occasions at least six
hours apart, was detected [23].
Blood samples were collected at the time the OGTT was
performed to determine fasting levels of glucose, HbA1c,
insulin, total, HDL-cholesterol, LDL- cholesterol, VLDL-
cholesterol, and triglycerides. A 75 g OGTT was performed
six weeks after delivery in those patients that presented
glucose intolerance during pregnancy to check if they had
returned or not to a normal glucose tolerant state.
All glucose determinations were conducted using glucose
oxidase method (Glucose-analyzer II Beckman, Fullerton,
CA, USA). Home blood glucose monitoring was per-
formed with an Accu-chek Advantage II Glucometer
(Roche Diagnostics GmbH, Mannheim, Germany). Total,
LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, and
triglycerides were measured by enzymatic colorimetric
assay (Vitros 250, Ortho-Clinical Diagnostics, Rochester,
New York, USA). HbA1c was determined by HPLC (high
performance liquid column) method (Dia-Stat analyzer,
Bio-Rad Laboratories, Hercules, CA, USA), and insulin
using a specific radioimmunoassay kit (Linco Research, St.
Charles, MO) with an intra and an interassay variation of
2.2 to 4.4% and 2.9 to 6.0%, respectively. Laboratory
quality standards were routinely evaluated.
Newborn data collected included birth weight, length,
ponderal index, gender, gestational age at delivery, Apgar
scores, perinatal morbidity, and congenital malforma-
tions. Births were defined as preterm if gestational age was
< 37 weeks. Ponderal index was calculated obtaining the
ratio between 100 times the weight (in grams) and the
cube of the length (in cm). The relation of newborns
weight to gestational age was done according to
Lubchenco's classification [24].
As there is no definition for MS in pregnancy, we adopted
the following: any one of the two primary criteriaDiabetology & Metabolic Syndrome 2009, 1:3 http://www.dmsjournal.com/content/1/1/3
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[impaired glycemic profile and/or impaired OGTT, plus at
least two of the following secondary criteria: hypertension
(systolic blood pressure > 140 mmHg or a diastolic blood
pressure > 90 mmHg on at least two occasions at least six
hours apart); dyslipidemia (plasma triglycerides ≥ 2 SD
above the mean of the control group and/or low HDL-
Cholesterol < 39 mg/dl) and obesity (BMI ≥ 30 Kg/m2
and/or waist ≥ 2 SD above the mean of pregnant women
belonging to the control group)] [25-28].
The homeostasis model assessment (HOMA) was calcu-
lated to determine the degree of β-cell function (%) and
insulin sensitivity (or resistance) (%S), using a computer
program (HOMA2 model) that analyzes quantitatively
these data [29].
Statistical analysis
Data were presented as mean ± standard deviation (SD) or
percentages. Analysis of variance (ANOVA) with Tukey
post-test was performed to compare means for continu-
ous variables with normal distribution. Kruskal-Wallis
with Dunn post-test was performed when the supposition
of homocedasticity and normality of distribution were
not attempted. Fisher's exact test or Chi-square test plus
Odds ratio (with 95% CI) was performed for proportions
comparisons. The significance level adopted for all tests
was < 0.05.
Results
One hundred and thirty six patients were enrolled in the
study. All of them completed the protocol. Data were
available from 46 control group patients (IA group), 40
mild hyperglycemic (IB group), 17 GDM (IIA group) and
33 overt GDM (IIB group).
Women with overt diabetes were older (p < 0.002), had
lower education levels (p < 0.001), lower family income (p
< 0.001), were about 5 cm shorter (p < 0.001), and had
approximately 3 cm shorter legs (p = 0.014) than those
from the normoglycemic group. At birth, the overt GDM
women were shorter (p = 0.05) and weighted less (p =
0.042) than control group. Prepregnancy, they had higher
BMI (p = 0.001), larger waist (p < 0.001), higher systolic (p
= 0.003) and diastolic blood pressure (p  = 0.003). At
screening, they had higher BMI (p < 0.001), larger waist (p
< 0.001), larger waist-to-hip ratio (p  = 0.002), higher
systolic (p = 0.002) and diastolic (p = 0.02) blood pres-
sure, higher fasting glucose (p < 0.001), HbA1c (p < 0.001),
triglycerides (p = 0.016), VLDL (p = 0.037), and lower
HDL (p = 0.014) cholesterol. Women with mild hypergly-
cemia (IB group) also had lower education level (p  <
0.001) and shorter legs (p = 0.014) than those from the
control group (Tables 1 and 2).
The results of HOMA are shown in Figure 1. The overt dia-
betes group showed significant increase in HOMA-IR val-
ues compared with control group (Fig. 1A; p < 0.05). They
also exhibited decreased β-cell function, and reduced
peripheral insulin sensitivity (as judged by the %β and
%S, respectively), when compared to the normoglycemic
group (Fig. 1B,C, respectively; p < 0.05).
There was a significantly increasing prevalence of MS from
the control group until the overt GDM group: 0.00%,
20.0%, 23.5%, 36.4% (p < 0.001 IA vs IB, IIA, IIB). The
prepregnancy independent predictors of MS during preg-
nancy were: previous history of GDM with insulin use OR
= 12.90 [95% CI (1.39119.76)] (p = 0.02), BMI > 25 OR =
11.00 [95% CI (4.1228.95)] (p < 0.001), hypertension OR
Table 1: Sociodemographic and clinical characteristics of the cohort according to glucose tolerance status (IA = normal glucose 
tolerance; IB = Impaired glycemic profile; IIA = Impaired 100 g OGTT; IIB = Impaired 100 g OGTT and glycemic profile).
Variables Groups p-value
IA IB IIA IIB
Number 46 40 17 33
Age (years) 28.7 ± 5.2 28.8 ± 6.4 31.4 ± 5.0 33.1 ± 5.6 0.002(1)
W h i t e  ( % ) 8 9 . 17 7 . 58 2 . 46 0 . 6 0 . 0 2 5 (2)
Education level (school years) 12.0 ± 3.6 10.7 ± 4.7 9.5 ± 4.6 7.1 ± 5.4 <0.001(3)
Family income 9.7 ± 5.4 7.7 ± 5.8 8.3 ± 5.4 3.5 ± 3.6 <0.001(4)
Diabetes in first degree relatives (%) 70.5 67.5 82.4 78.8 0.556
S m o k i n g  ( % ) 2 1 . 72 7 . 53 5 . 32 7 . 3 0 . 7 4 3
Maternal birth weight (g)* 3429 ± 617 3406 ± 480 3180 ± 808 2965 ± 757 0.042(5)
Maternal birth length (cm)* 48.9 ± 2.2 48.7 ± 1.9 47.6 ± 2.3 47.1 ± 3.5 0.05(6)
Maternal ponderal index* 2.8 ± 0.2 2.8 ± 0.2 2.9 ± 0.2 3.0 ± 0.6 0.224
(1) p < 0.05 IIB vs IA, IB;
(2) p < 0.01 IA vs IIB;
(3) p < 0.05 IIB vs IB, IIA, IA; IB vs IA;
(4) p < 0.01 IA vs IIB; IB vs IIB; IIA vs IIB;
(5) p < 0.05 IIB vs IB, IA;
(6) p < 0.05 IIB vs IA.
* Maternal weight, length and ponderal index at birthDiabetology & Metabolic Syndrome 2009, 1:3 http://www.dmsjournal.com/content/1/1/3
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= 10.04 [95% CI (3.2537.97)] (p < 0.001), previous his-
tory of GDM without insulin use OR = 6.08 [95% CI
(1.6622.21)] (p < 0.001), diabetes in first degree relatives
OR = 3.70 [95% CI (1.2011.38)] (p = 0.02), non-Cauca-
sian ethnicity OR = 2.94 [95% CI (1.236.67)] (p = 0.02),
history of prematurity OR = 2.84 [95% CI (1.067.57)] (p
= 0.03) and of polihydramnios OR = 2.57 [95% CI
(1.175.62)] (p = 0.02).
Acanthosis nigricans was the most prevalent physical
marker of insulin resistance at screening (19.6, 42.5, 58.8
and 69.7%; for IA, IB, IIA and IIB groups, respectively) (p
< 0.001 IA vs IB, IIA, IIB); followed by obesity (13.0, 40.0,
58.8 and 60.6%; for IA, IB, IIA and IIB groups, respec-
tively) (p < 0.001 IA vs IIA, IIB); hypertension (6.5, 17.5,
17.6 and 39.4%; for IA, IB, IIA and IIB groups, respec-
tively) (p < 0.005 IA vs IB, IIA, IIB), and large waist circum-
ference (2.2, 15.0, 35.4 and 24.2%; for IA, IB, IIA and IIB
groups, respectively) (p < 0.05 IA vs IB; IB vs IIB; p < 0.01
IA vs IIA, IIB).
Independently of glucose tolerance status, the whole
group was classified as having or not having MS, and the
prevalence of adverse maternal and perinatal outcomes
Table 2: Anthropometric (prepregnancy and at screening) and laboratory characteristics at screening according to glucose tolerance 
status during pregnancy
Variables Groups p-value
IA IB IIA IIB
Height (meter) 1.65 ± 0.07 1.64 ± 0.05 1.61 ± 0.05 1.60 ± 0.05 0.001(1)
Legs length (cm) 76.0 ± 4.8 75.3 ± 4.0 73.3 ± 4.1 73.1 ± 4.1 0.014(2)
BMI
Prepregnancy 23.1 ± 4.5 25.8 ± 6.1 27.8 ± 7.6 28.5 ± 6.9 0.001(3)
At screening 25.6 ± 4.3 29.3 ± 6.1 31.0 ± 6.9 31.4 ± 6.0 <0.001(4)
Waist
Prepregnancy 69.6 ± 5.1 81.5 ± 11.3 90.3 ± 18.6 101.8 ± 15.1 <0.001(5)
At screening 95.9 ± 10.1 104.5 ± 11.3 107.6 ± 14.4 108.2 ± 9.8 <0.001(6)
Waist-to-hip ratio
Prepregnancy 0.76 ± 0.06 0.76 ± 0.05 0.86 ± 0.11 0.87 ± 0.11 0.040
At screening 0.93 ± 0.07 0.95 ± 0.07 0.97 ± 0.04 0.99 ± 0.07 0.002 (7)
Systolic blood pressure (mmHg)
Prepregnancy 108.4 ± 7.8 115.5 ± 23.3 114.7 ± 14.1 125.4 ± 25.8 0.003(8)
At screening 107.7 ± 9.9 111.0 ± 12.5 114.7 ± 11.7 120.6 ± 17.6 0.002(9)
Diastolic blood pressure (mmHg)
Prepregnancy 71.0 ± 8.2 75.0 ± 14.1 75.8 ± 9.3 81.2 ± 12.9 0.003(10)
At screening 71.5 ± 9.2 74.5 ± 10.8 76.4 ± 11.1 79.3 ± 12.2 0.02(11)
At screening
Fasting glucose(mg/dl) 73.7 ± 8.7 74.8 ± 9.6 87.2 ± 11.7 114.4 ± 23.6 <0.001(12)
HbA1c (%) 4.57 ± 0.45 4.95 ± 0.59 5.15 ± 0.71 5.98 ± 1.00 <0.001(13)
Total cholesterol(mg/dl) 229.2 ± 43.5 236.7 ± 44.5 221.4 ± 42.3 195.5 ± 43.0 0.001(14)
LDL cholesterol(mg/dl) 124.2 ± 41.5 130.2 ± 37.8 111.6 ± 34.6 94.2 ± 33.0 0.001(15)
HDL cholesterol(mg/dl) 69.0 ± 16.9 66.1 ± 16.4 73.1 ± 21.3 57.8 ± 16.2 0.014(16)
VLDL cholesterol(mg/dl) 34.8 ± 12.0 39.4 ± 13.3 36.5 ± 13.9 43.4 ± 11.7 0.037(17)
Triglycerides (mg/dl) 174.3 ± 60.4 215.7 ± 131.7 182.8 ± 69.5 217.3 ± 58.5 0.016(18)
(1) p < 0.05 IIB vs IB, IA; IIA vs IA;
(2) p < 0.05 IA vs IIB, IIA, IB;
(3) p < 0.05 IA vs IIA, IIB;
(4) p < 0.05 IA vs IB, IIA, IIB;
(5) p < 0.05 IA vs IB, IIA, IIB;
(6) p < 0.05 IA vs IB, IIA, IIB;
(7) p < 0.05 IA vs IIA, IIB; IB vs IIB;
(8) p < 0.01 IA vs IIB;
(9) p < 0.01 IA vs IIB;
(10) p < 0.01 IA vs IIB;
(11) p < 0.05 IA vs IIB;
(12) p < 0.001 IA vs IIB, IB vs IIB; p < 0.01 IA vs IIA; p < 0.05 IB vs IIA, IIA vs IIB;
(13) p < 0.001 IA vs IIB; IB vs IIB;
(14) p < 0.05 IIB vs IIA, IA, IB;
(15) p < 0.05 IIB vs IA, IB;
(16) p < 0.05 IIB vs IA, IIA;
(17) p < 0.05 IA vs IIB;
(18) p < 0.05 IA vs IIB;Diabetology & Metabolic Syndrome 2009, 1:3 http://www.dmsjournal.com/content/1/1/3
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were analyzed. Women that presented MS showed a sig-
nificant association with the occurrence of preeclampsia
OR = 4.08 [95% CI (1.0815.40)] (p < 0.0001). The off-
spring of mothers with MS presented significantly higher
prevalence of LGA OR = 2.97 [95% CI (1.048.47)] (p =
0.0409), overweight (ponderal index) OR = 4.08 [95% CI
(1.6510.18)] (p = 0.001), Apgar score < 7 at 1 min OR =
6.06 [95% CI (1.4526.94)] (p = 0.0083) and 2 min OR =
4.81 [95% CI (1.2119.09)] (p = 0.041), prematurity OR =
3.37 [95% CI (1.308.71)] (p = 0.031), and any kind of
adverse perinatal outcomes OR = 2.88 [95% CI
(1.226.84)] (p = 0.0135).
Discussion
There is an association between the worsening of glucose
tolerance with an increasing prevalence of MS. The wors-
ening of glucose tolerance was directly associated with age
[30], non-Caucasian ethnicity, lower education levels,
lower family income [31], lower weight and length at
birth [32], lower height and shorter legs in adulthood
[33], higher BMI, larger waist, larger waist-to-hip ratio
[28,34], higher systolic, and diastolic blood pressure [35].
Laboratory findings of lower HDL cholesterol and higher
levels of VLDL cholesterol and triglycerides were also asso-
ciated with the worsening of glucose tolerance. Many of
these features are components of MS. This led us to
explore the metabolic nature of mild gestational hypergly-
cemia and GDM as part of the insulin resistance syn-
drome.
Using the HOMA2 model to assess beta cell function and
peripheral insulin sensitivity, we have found that preg-
nant women that presented any degree of glucose intoler-
ance also showed higher degree of insulin resistance at
screening. Patients that presented mild hyperglycemia
(impaired glycemic profile and normal OGTT) showed
higher values of HOMA-IR and lower peripheral insulin
sensitivity, although not statistically significant, com-
pared with the control group, showing that besides pre-
senting insulin resistance, they also had a compensatory
hyperinsulinemia. The GDM group (impaired OGTT and
normal glycemic profile) had high HOMA-IR values,
which were not also statistically significant; however
peripheral insulin sensitivity was significantly decreased,
pointing to the presence of some insulin action defi-
ciency. Finally, the overt GDM group (both impaired
tests) showed the highest values of HOMA-IR probably
due to a decreased insulin peripheral action and impaired
β-cell function, what points to the presence of both patho-
physiological mechanisms that are present in GDM as
well as in DM2: insulin resistance and insulin deficiency
(Figure 1).
Our study was limited by the small number of partici-
pants; so more research is warranted analyzing more
patients.
Conclusion
In conclusion, our data support: that the prevalence of MS
increases with the worsening of glucose tolerance; the
important role of glycemic profile as a diagnostic test to
identify metabolic abnormalities related to MS in preg-
nancy even in the presence of a normal OGTT, in patients
that are not currently classified as having GDM.
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Evaluation of peripheral insulin sensitivity and β-cell function in patients by HOMA2 model Figure 1
Evaluation of peripheral insulin sensitivity and β-cell function in patients by HOMA2 model. These graphs show: 
(A) significant increase of HOMA-IR values (A), decreased β-cell-function (B), and decreased peripheral insulin sensitivity (C) 
in IIB group when compared with IA group. IIA group of patients also exhibited decreased peripheral insulin sensitivity, com-
pared with IA group (C). The values are mean ± SD. asignificantly different vs IA; bvs IB. p < 0.05.Publish with BioMed Central    and   every 
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